<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03362931</url>
  </required_header>
  <id_info>
    <org_study_id>1924-701-007</org_study_id>
    <nct_id>NCT03362931</nct_id>
  </id_info>
  <brief_title>Safety and Effectiveness of the XEN45 Glaucoma Treatment System in Patients With Angle Closure Glaucoma</brief_title>
  <official_title>A Prospective, Multicenter Clinical Trial Designed to Evaluate the Safety and Effectiveness of the XEN45 Glaucoma Treatment System in Patients With Angle Closure Glaucoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and IOP-lowering effectiveness of XEN in patients with&#xD;
      Angle Closure Glaucoma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 19, 2018</start_date>
  <completion_date type="Anticipated">April 8, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 8, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients achieving at least a 20% reduction from baseline Hour 0 IOP while on the same number or fewer IOP lowering medications</measure>
    <time_frame>Baseline to Month 12</time_frame>
    <description>IOP will be measured using a Goldmann applanation tonometer</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline the number of concomitant IOP-lowering medications</measure>
    <time_frame>Baseline to Month 12</time_frame>
    <description>The number of concomitant IOP-lowering medications following implantation will be compared with the number prior to implantation.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">65</enrollment>
  <condition>Glaucoma</condition>
  <condition>Angle-Closure</condition>
  <arm_group>
    <arm_group_label>XEN45 Glaucoma Treatment System (hereafter referred to as XEN)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>XEN45 unilaterally implanted in the study eye</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>XEN45</intervention_name>
    <description>XEN45 unilaterally implanted in the study eye</description>
    <arm_group_label>XEN45 Glaucoma Treatment System (hereafter referred to as XEN)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of ACG defined as areas of iridotrabecular contact present in â‰¥ 2 quadrants&#xD;
             and glaucomatous damage to optic disc and visual field, in the study eye&#xD;
&#xD;
          -  Study eye has healthy, free, and mobile conjunctiva in the target quadrant&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Uncontrolled systemic disease (eg, diabetes, hypertension)&#xD;
&#xD;
          -  Known history of bleeding disorder or prolonged bleeding after surgery or those on&#xD;
             pharmacologic blood thinners other than aspirin (up to 100 mg/day)&#xD;
&#xD;
          -  History of dermatologic keloid formation&#xD;
&#xD;
          -  Open angle glaucoma, active acute angle closure attack, congenital glaucoma, juvenile&#xD;
             glaucoma, secondary glaucoma in the study eye&#xD;
&#xD;
          -  History of following surgeries in the study eye:&#xD;
&#xD;
               -  incisional refractive surgery (eg, radial keratotomy), other than astigmatic&#xD;
                  keratotomy or limbal relaxing incisions&#xD;
&#xD;
               -  corneal graft including partial grafts such as Descemet's stripping endothelial&#xD;
                  keratoplasty and Descemet's membrane endothelial keratoplasty&#xD;
&#xD;
               -  previous laser or incisional intraocular surgery that might interfere with the&#xD;
                  outcome of this trial&#xD;
&#xD;
          -  Previous glaucoma shunt implantation in the target quadrant in the study eye&#xD;
&#xD;
          -  Active or history of chronic uveitis in the study eye&#xD;
&#xD;
          -  Unable to discontinue contact lens wear in the study eye during the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ALLERGAN INC.</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Marsden Eye Specialists Parramatta /ID# 232761</name>
      <address>
        <city>Paramatta</city>
        <state>New South Wales</state>
        <zip>2150</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eye Surgery Associates P/L ATF Eye Surgery Associates Unit Trust /ID# 232765</name>
      <address>
        <city>Vermont South</city>
        <state>Victoria</state>
        <zip>3133</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de loeil des Laurentides /ID# 232780</name>
      <address>
        <city>Boisbriand</city>
        <state>Quebec</state>
        <zip>J7H 0E8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ophthalmology Clinic Bellevue /ID# 232782</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1V 1G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Ophthalmology and Visual Sciences /ID# 232906</name>
      <address>
        <city>Mongkok</city>
        <zip>999077</zip>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital /ID# 233099</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center /ID# 233075</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center /ID# 232949</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nuh Medical Centre /ID# 232905</name>
      <address>
        <city>Singapore</city>
        <zip>119082</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tan Tock Seng Hospital /ID# 233014</name>
      <address>
        <city>Singapore</city>
        <zip>308433</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital /ID# 232948</name>
      <address>
        <city>Taipei City</city>
        <state>Taipei</state>
        <zip>11217</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tri-Service General Hospital /ID# 233079</name>
      <address>
        <city>Taipei City</city>
        <state>Taipei</state>
        <zip>11490</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Buddhist Tzu Chi General Hospital /ID# 232664</name>
      <address>
        <city>Hualien</city>
        <zip>97002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Essex County Hospital /ID# 232804</name>
      <address>
        <city>Colchester</city>
        <state>Essex</state>
        <zip>CO4 5JR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manchester University NHS Foundation Trust /ID# 232808</name>
      <address>
        <city>Manchester</city>
        <state>Lancashire</state>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Victoria Hospital /ID# 232812</name>
      <address>
        <city>East Grinstead</city>
        <state>West Sussex</state>
        <zip>RH19 3DZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Alexandra Eye Pavilio /ID# 233052</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH3 9HA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Surrey County Hosp NHS /ID# 233028</name>
      <address>
        <city>Guildford</city>
        <zip>GU2 7XX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western Eye Hospital Imperial College Healthcare NHS Trust /ID# 232916</name>
      <address>
        <city>London</city>
        <zip>NW1 5QH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Hong Kong</country>
    <country>Korea, Republic of</country>
    <country>Singapore</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://AllerganClinicalTrials.com</url>
    <description>Additional information on study locations near you may be found at AllerganClinicalTrials.com.</description>
  </link>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>November 30, 2017</study_first_submitted>
  <study_first_submitted_qc>November 30, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 5, 2017</study_first_posted>
  <last_update_submitted>June 29, 2021</last_update_submitted>
  <last_update_submitted_qc>June 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Angle-Closure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>For details on when studies are available for sharing, please refer to the link below</ipd_time_frame>
    <ipd_access_criteria>Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Use Agreement (DUA). For more information on the process, or to submit a request, visit the following link.</ipd_access_criteria>
    <ipd_url>https://vivli.org/ourmember/abbvie/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

